Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $2.2 million.

  • Utah Medical Products' Accumulated Expenses fell 792.28% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 792.28%. This contributed to the annual value of $3.1 million for FY2024, which is 2232.94% down from last year.
  • Per Utah Medical Products' latest filing, its Accumulated Expenses stood at $2.2 million for Q3 2025, which was down 792.28% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' Accumulated Expenses registered a high of $5.0 million during Q1 2023, and its lowest value of $1.5 million during Q2 2025.
  • In the last 5 years, Utah Medical Products' Accumulated Expenses had a median value of $3.7 million in 2023 and averaged $3.6 million.
  • As far as peak fluctuations go, Utah Medical Products' Accumulated Expenses surged by 5891.42% in 2022, and later crashed by 5114.33% in 2025.
  • Over the past 5 years, Utah Medical Products' Accumulated Expenses (Quarter) stood at $3.0 million in 2021, then surged by 58.91% to $4.7 million in 2022, then fell by 16.89% to $3.9 million in 2023, then decreased by 22.33% to $3.1 million in 2024, then fell by 26.72% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $1.5 million for Q2 2025, and $3.4 million during Q1 2025.